PMID- 26521870
OWN - NLM
STAT- MEDLINE
DCOM- 20160613
LR  - 20151102
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 135
IP  - 11
DP  - 2015
TI  - [Basic Research on Neurotrophic Factors and Its Application to Medical Uses].
PG  - 1213-26
LID - 10.1248/yakushi.15-00219 [doi]
AB  - The author has studied nerve growth factor (NGF) and its family of neurotrophic 
      factors (neurotrophins) for over 40 years. During the first 20 years, my 
      laboratory established a highly sensitive enzyme immunoassay for NGF and analyzed 
      the regulatory mechanism of NGF synthesis in cultured primary cells. Fibroblast 
      cells cultured from peripheral organs such as the heart and astrocytes from the 
      brain produced a substantial amount of NGF in a growth-dependent manner. 
      Furthermore, synthesis of NGF in these cells could be upregulated by catechol 
      compounds including catecholamines. This observation might explain a 
      physiological relation between the level of NGF mRNA and the density of 
      innervation in the peripheral sympathetic nervous systems. Over the subsequent 20 
      years, my laboratory investigated the physiological functions of neurotrophic 
      factors, including neurotrophins, during development or post-injury and found 
      that brain-derived neurotrophic factor (BDNF) plays a role in the formation of 
      the laminar structure of the cerebral cortex. In addition, my laboratory 
      discovered that endogenous glial cell line-derived neurotrophic factor (GDNF) 
      contributes to the amelioration of motor activity after spinal cord injury. 
      Therefore we aimed to develop low-molecular weight compounds that generate 
      neurotrophic factor-like intracellular signals to protect or ameliorate 
      neurological/psychiatric diseases. 2-Decenoic acid derivatives and other similar 
      molecules could protect or ameliorate in animal models of mood disorders such as 
      depression and enhance recovery from spinal cord injury-induced motor paralysis. 
      Compounds that can generate neurotrophin-like signals in neurons are expected to 
      be developed as therapeutic drugs for certain neurological or psychiatric 
      disorders.
FAU - Furukawa, Shoei
AU  - Furukawa S
AD  - Laboratory of Molecular Biology, Department of Biofunctinal Analysis, Gifu 
      Pharmaceutical University.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Nerve Growth Factors)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mental Disorders/drug therapy
MH  - *Nerve Growth Factors/biosynthesis/physiology/therapeutic use
MH  - Nervous System Diseases/drug therapy
EDAT- 2015/11/03 06:00
MHDA- 2016/06/14 06:00
CRDT- 2015/11/03 06:00
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2016/06/14 06:00 [medline]
AID - 10.1248/yakushi.15-00219 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2015;135(11):1213-26. doi: 10.1248/yakushi.15-00219.